Genvor INC 10-Q quarterly reports

Genvor Incorporated's Q3 2026 Form 10-Q reveals significant operating losses and a continued lack of revenue, highlighting ongoing concerns about the company's liquidity and ability to continue as a going concern.

Genvor Incorporated files its Q2 2026 Form 10-Q, detailing increased R&D spending, significant stock-based compensation adjustments, and a new financing agreement.

Genvor Incorporated filed an amendment to its Q1 2026 quarterly report to correct typographical errors and update certifications, while reiterating significant financial challenges including a going concern warning.

Genvor Incorporated reported a significantly reduced net loss in Q1 2026, driven by lower operating expenses, while continuing to develop its AI-accelerated peptide technology despite ongoing liquidity concerns.

Genvor Incorporated reported a significant increase in net loss for the nine months ended June 30, 2025, raising substantial doubt about its ability to continue as a going concern despite R&D advancements and a Bayer partnership.

Genvor Incorporated reported a significant net loss for the six months ended March 31, 2025, and faces substantial doubt about its ability to continue as a going concern, despite recent capital raises and technological advancements.